Trial reportEBioMedicine2015
A Retrospective Analysis of the Significance of Haemoglobin SS and SC in Disease Outcome in Patients With Sickle Cell Disease and Dengue Fever.
Trial report in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pooled it
- EHA Guidelines on the management of children and adults with hemoglobin SC disease.HemaSphere · 2026Article
- Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025.British journal of haematology · 2026Article
- Sickle cell disease implicated in the development of severe dengue: A pediatric case series.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Dengue fever uncovers a late diagnosis of sickle cell disease- a case report.BMC infectious diseases · 2025Article
- Infections in sickle cell disease.Haematologica · 2025Review
- Clinical and prognostic relevance of sST2 in adults with dengue-associated cardiac impairment and severe dengue.PLoS neglected tropical diseases · 2022Article
- Detection of Potential Arbovirus Infections and Pregnancy Complications in Pregnant Women in Jamaica Using a Smartphone App (ZIKApp): Pilot Evaluation Study.JMIR formative research · 2022Article
- Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.American journal of hematology · 2022Article
- Severity and Outcomes of Dengue in Hospitalized Jamaican Children in 2018-2019 During an Epidemic Surge in the Americas.Frontiers in medicine · 2022Article
- A fatal case report of antibody-dependent enhancement of dengue virus type 1 following remote Zika virus infection.BMC infectious diseases · 2021Article
- Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review.Frontiers in pediatrics · 2020Review
- Fatal Sickle Cell Disease and Zika Virus Infection in Girl from Colombia.Emerging infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the significance of haemoglobin genotype in dengue fever severity. This study was undertaken to determine the case fatality ratio and the impact of genotype in patients with sickle cell disease and confirmed dengue fever.
methodsThis retrospective analysis included 40 patients with confirmed dengue and sickle cell disease, during the study period (2010-2012).
findingsThere was a significantly higher case fatality ratio, 12.5% among patients with either haemoglobin SC disease or homozygous SS disease when compared to that of the general population 0.41% (p < 0.0001). The unadjusted odds of dying among those with haemoglobin SC disease compared with the group with homozygous SS disease was OR = 4.4 (95% CI 0.6 to 31.7). The predictors of mortality independent of sickle cell disease genotype were haemoglobin concentration at presentation OR = 0.57 (95% CI, 0.35 to 0.94) and the change in haemoglobin concentration from steady state OR = 0.59 (95% CI, 0.37 to 0.94). Adjusting for haemoglobin concentration at presentation increased the risk of death for the SC genotype relative to SS genotype OR = 13.4 (95% CI 1.1 to 160.3).
interpretationThe risk of fatal dengue may be higher among patients with a relatively mild genotype (haemoglobin SC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.